Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07321210 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC)

Study acronym: UTLUND
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoint(s) modified Start date changed from estimate of Jan 1, 2026 to Sep 1, 2025 · Study title shortened, about 4 wordsv2 Show 2 more changesShow less
    • Start date changed from estimate of Jan 1, 2026 to Sep 1, 2025
    • Study title shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn if adding a template lymph node dissection (TLND) to the standard surgery for upper tract urothelial cancer (UTUC) can improve patient survival and prevent the cancer from recurrence. The main questions it aims to answer are: Do patients who receive standard surgery with LND live longer without their cancer returning? Is adding LND safe, and how does it affect surgery-related complications? Researchers will compare the group receiving standard surgery plus LND to the group receiving standard surgery alone to see if adding LND is more effective. Participants will: Be randomly assigned to one of the two surgical groups. Undergo their assigned surgery and recover in the hospital. Attend regular follow-up visits for checkups and scans for 5 years to monitor for cancer recurrence, with the possibility of long-term follow-up extending to 10 years.
Trial Details
NCT Number NCT07321210
Lead Sponsor Tianjin Medical University Second Hospital
Collaborators: Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Sun Yat-Sen University Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin Third Central Hospital
Conditions Upper Tract Urothelial Carcinoma, Lymph Node Dissection
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov